A股異動丨人造肉概念股表現活躍 美國人造肉第一股Beyond Meat將於浙江建廠
格隆匯9月9日丨人造肉概念股表現活躍,東寶生物漲停,龍頭雙塔食品漲超5%。從Beyond Meat官網獲悉,該公司最新的一份聲明提到,Beyond Meat將在浙江建工廠,工廠將位於緊鄰上海的嘉興經濟技術開發區,工廠將在中國生產Beyond Meat品牌的產品包括牛肉、豬肉和雞肉在內的植物肉製品,預計“在幾個月內開始試產,2021年初開始全面生產。Beyond Meat此前在中國市場與星巴克、盒馬等合作。4月星巴克在中國推出基於植物的午餐菜單,包含用植物肉做的經典千層麪、青醬意麪和美式酸辣醬大卷。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.